Relay Therapeutics, Inc.RLAYEarnings & Financial Report
Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.
RLAY Q4 FY2025 Key Financial Metrics
Revenue
$7.0M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
Relay Therapeutics, Inc. Q4 FY2025 Financial Summary
Relay Therapeutics, Inc. reported revenue of $7.0M for Q4 FY2025, with a net profit of N/A (N/A margin).
Key Financial Metrics
| Total Revenue | $7.0M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Relay Therapeutics, Inc. Annual Revenue by Year
Relay Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $10.0M).
Relay Therapeutics, Inc. Quarterly Revenue & Net Profit History
Relay Therapeutics, Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $7.0M | — | N/A | N/A |
| Q3 FY2025 | $0 | — | $-74.1M | N/A |
| Q1 FY2025 | $7.7M | -23.3% | $-77.1M | -1003.6% |
| Q4 FY2024 | $0 | — | N/A | N/A |
| Q3 FY2024 | $0 | — | $-88.1M | N/A |
| Q2 FY2024 | $0 | — | $-92.2M | N/A |
| Q1 FY2024 | $10.0M | +4327.9% | $-81.4M | -813.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $10.0M | $0 | $0 | $0 | $7.7M | $0 | $7.0M |
| YoY Growth | 4327.9% | N/A | N/A | N/A | -23.3% | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Assets | $841.4M | $772.5M | $930.1M | $871.3M | $799.4M | $670.0M | $621.3M |
| Liabilities | $95.7M | $90.8M | $91.3M | $93.5M | $78.3M | $62.3M | $54.3M |
| Equity | $745.8M | $681.7M | $838.9M | $777.8M | $721.1M | $607.7M | $567.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-50.3M | $-65.8M | $-75.1M | $-249.1M | $-73.2M | $-62.1M | $-235.5M |